The selection of therapy is most appropriately based on knowledge of an individualâ€™s risk of tumor recurrence balanced against the short-term and long-term risks of adjuvant treatment.
This approach allows clinicians to help individuals determine if the gains anticipated from treatment are reasonable for their situation.
An Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis included 11 trials that began from 1976 to 1989 in which women were randomly assigned to receive regimens containing anthracyclines (e.g., doxorubicin or epirubicin) or CMF (cyclophosphamide, methotrexate, and fluorouracil [5-FU]).